BioSculpture Technology, Inc. Pitch Deck (2016) Breakdown

BioSculpture Technology (BST) presents a specialized medical device play focused on the multibillion-dollar obesity and cosmetic surgery markets. The deck, dated September 2016, highlights a shift from their established Airbrush Liposculptor line to a novel Endoscopic Visceral Lipectomy (EVL) device designed to treat obesity and type 2 diabetes. Financially, the company projected a steep revenue climb from $0 in 2016 to $44.5 million by 2020, contingent on the success of their patented Twin-Cannula Assisted Liposuction (TCAL) technology. The offering is structured as a Tier 2 Regulation A, se…

Key takeaways

• The company is raising $5,000,000 through a Tier 2 Regulation A offering at a price of $3.50 per share (Slide 19).
• BST claims a large IP portfolio including three patents on method and device with numerous U.S. patents pending (Slide 3).
• Financial projections estimate a jump from $0 sales in 2016 to over $44.5 million in sales by 2020 (Slide 3).
• The core technical differentiator is the 'Twin-Cannula' system, which uses an adjustable reciprocation stroke of 1.3 to 2 inches to reduce surgeon fatigue and patient trauma (Slide 10).
• The EVL device is positioned as a safer alternative to bariatric surgery, avoiding the need to cut into the stomach or rearrange 'alimentary plumbing' (Slide 12).
• Market data cites that 2/3 of the U.S. population is overweight and obesity-related expenditures exceed $2 trillion worldwide (Slide 7).
• The sales strategy involves a 20% promotional budget and direct marketing to 'podium doctors' and Key Opinion Leaders (Slide 16).
• The deck omits a comprehensive team slide, listing only CEO Robert L. Cucin, M.D., J.D., M.B.A. on the contact page (Slide 22).

Frequently asked questions

What is the primary product BioSculpture Technology is pitching?

The company pitches two main product lines: the Airbrush Liposculptor (IIE and III) for cosmetic fat removal and the EVL (Endoscopic Visceral Lipectomy) device for treating obesity and metabolic syndrome. The technical foundation for both is their patented Twin-Cannula Assisted Liposuction (TCAL) technology, which uses a stationary outer cannula and a reciprocating inner cannula to remove fat more efficiently than traditional methods.

What are the specific terms of the investment offering?

According to Slide 19, BioSculpture Technology filed a Form 1-A for a Tier 2 Regulation A offering. They sought to sell 1,428,571 common shares at $3.50 per share to raise a total of $5,000,000. The slide notes that the offering was qualified on September 1, 2016, and included a success fee for participating broker-dealers.

How does the company justify its market opportunity?

BST points to the global obesity crisis, noting that 2.1 billion people worldwide are obese, a figure expected to reach 50% of the population by 2030. They specifically target the gap between cosmetic liposuction ($668M spent in 2015) and bariatric surgery ($1.4B spent in 2014), claiming their EVL device offers the benefits of weight loss surgery without the invasive risks of gastric bypass.

What are the projected financials for the company?

The company provided a five-year financial forecast on Slide 3. They projected $0 in sales for 2016 with a net loss of $2.57 million. By 2018, they expected to turn profitable with $20.05 million in sales and $2.68 million in net income. By 2020, the projection reaches $44.5 million in sales and $4.76 million in net income.

Who is leading the company according to the deck?

The only individual identified in the presentation is Robert L. Cucin, who holds M.D., J.D., and M.B.A. degrees. He is listed as the CEO on Slide 22. While the deck mentions 'Management' has extensive connections to research hospitals and Key Opinion Leaders on Slide 16, it does not name any other executives, board members, or advisors.

BioSculpture Technology, Inc. pitch deck: the facts

Company

BioSculpture Technology, Inc.

Year

2016

Stage

Commercial-stage (Reg A+ Offering)

Slides

22

Sector

Medical Device

Deck type

Investor Presentation

Outcome

Not stated

Headquarters

West Palm Beach, FL

BioSculpture Technology, Inc. pitch deck PDF

The full BioSculpture Technology, Inc. deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the BioSculpture Technology, Inc. pitch deck was used for

This 2016 investor presentation is a 22‑slide commercial‑stage deck prepared for BioSculpture Technology, Inc.’s Tier 2 Regulation A+ offering, which was qualified by the U.S. SEC on September 1, 2016. The company sought to raise up to $5 million to fund development, clinical testing, and commercialization of its patented endoscopic visceral lipectomy (EVL) procedure and next‑generation Twin Cannula Assisted Liposuction (TCAL) devices. The deck positions BioSculpture as transitioning from traditional Airbrush Liposculptor TCAL liposuction systems into a disruptive minimally invasive visceral fat removal platform targeting obesity, metabolic syndrome, and type 2 diabetes. The Regulation A offering subsequently terminated on August 31, 2017, and the company later reported very limited subscriptions into the offering.

Business model: BioSculpture Technology, Inc. develops and commercializes patented minimally invasive aspiration systems and procedures for fat removal, including Twin Cannula Assisted Liposuction (TCAL) devices and an endoscopic visceral lipectomy (EVL) procedure targeting obesity, metabolic syndrome, and type 2 diabetes mellitus.

Year

2016–2017.

Headquarters

1701 South Flagler Drive, Suite 607, West Palm Beach, Florida 33401, United States.

Industry

Medical devices focused on liposuction and endoscopic obesity treatments.

Round: Tier 2 Regulation A offering (Reg A+) targeting commercialization and development funding for medical devices.

Raising: Up to $5,000,000 in a Tier 2 Regulation A offering qualified on September 1, 2016 and terminated on August 31, 2017.

Raised: Approximately $5,200 in gross proceeds from the sale of 1,500 shares as of June 3, 2016, during the Tier 2 Regulation A offering.

Use of funds as presented: Funding development, clinical testing, regulatory clearance efforts, and commercialization of the company’s endoscopic visceral lipectomy (EVL) procedure and related Twin Cannula Assisted liposuction devices, as part of a strategy to become a public company.

What happened after the BioSculpture Technology, Inc. deck

The 2016 commercial‑stage deck supported a Tier 2 Regulation A offering that was qualified by the SEC but ultimately appears to have raised only a small fraction of its $5 million target before terminating in August 2017; the company has since continued to develop its endoscopic visceral lipectomy (EVL) procedure and new Twin Cannula Assisted liposuction devices while discontinuing its legacy Airb

• Form 1‑A for a Tier 2 Regulation A offering filed with the SEC in 2016.
• SEC qualification of BioSculpture Technology, Inc.’s Tier 2 Regulation A offering on September 1, 2016, under file numbe
• Termination of the Regulation A offering on August 31, 2017, as noted in company investor materials and the dedicated IP
• Reported sales of 1,500 shares raising approximately $5,200 as of June 3, 2016, according to the company’s 2017 Form 1‑K
• Subsequent company disclosures that Airbrush Liposculptor systems were discontinued and are no longer sold or serviced,

What the BioSculpture Technology, Inc. deck got right

• Clear, qualified Regulation A structure for the capital raise. The deck is anchored by a clearly defined Tier 2 Regulation A offering, which was formally qualified by the SEC on September 1, 2016, giving investors regulatory transparency around the structure and timing of the raise. This lends procedural credibility compared to purely private offerings.
• Differentiated focus on visceral fat removal and metabolic disease. BioSculpture’s technology proposition combines established Twin Cannula Assisted Liposuction (TCAL) devices with a novel endoscopic visceral lipectomy (EVL) procedure aimed at removing metabolically harmful visceral fat, directly targeting obesity, metabolic syndrome, and type 2 diabetes. This integrated platform story differentiates the company from standard cosmetic liposuction players.
• Prototyped next‑generation products supporting the core EVL thesis. The company highlights a pipeline of three new products supporting EVL that had already been successfully prototyped, presenting a tangible R&D base rather than a purely conceptual technology. This suggests technical progress and a clear roadmap for productization, contingent on funding and regulatory work.
• Evidence‑based framing of visceral vs. subcutaneous fat. The deck leverages published clinical literature distinguishing visceral from subcutaneous fat and their respective health consequences, reinforcing the medical rationale for targeting visceral fat and situating EVL within a broader evidence‑based obesity treatment narrative. This helps frame the opportunity beyond cosmetic indications.
• Compelling alternative positioning versus bariatric surgery. By presenting its aspiration systems as minimally invasive and potentially safer or less morbid than bariatric surgery for some patients, the company articulates a clear competitive positioning in a large and growing obesity treatment market, which can be compelling for investors seeking disruptive alternatives.
• Consistent strategic focus on TCAL and EVL platforms. Company materials and later summaries consistently describe the same core technologies (TCAL, Airbrush Liposculptor, EVL) and clinical targets, suggesting a coherent and sustained strategic focus rather than frequent pivots. This strategic consistency can reassure investors about long‑term direction.

What could have been stronger

• Large mismatch between $5M Reg A raise target and actual subscriptions. The deck is built around a Tier 2 Regulation A raise of up to $5 million to fund EVL development and commercialization, but subsequent Form 1‑K disclosure shows that as of June 3, 2016 only 1,500 shares had been sold, raising about $5,200, highlighting a significant gap between fundraising target and demonstrated investor demand. This discrepancy is not addressed within the presentation itself, leaving prospective investors without context on subscription traction or revised plans.
• High regulatory and development risk with limited concrete milestones. The EVL procedure and related devices are central to the deck’s value proposition, yet company pipeline disclosures state that the three new products enabling EVL had been prototyped but had not yet been submitted for any regulatory clearance, and the offering proceeds were needed to complete development and bring them to market. This underscores substantial regulatory and execution risk that is only partly acknowledged via boilerplate forward‑looking statements rather than quantified timelines or milestones.
• Limited transparency on commercial traction of legacy TCAL products. Later company disclosures indicate that legacy Airbrush Liposculpture systems were discontinued and are no longer sold or serviced as production is being retooled for a new TCAL generation. For investors reviewing the 2016 deck in hindsight, this raises questions about the durability and revenue contribution of the existing product line that the deck had framed as commercial‑stage, without providing detailed historic sales data or customer adoption metrics.
• Heavy reliance on theoretical and mechanistic rationale without clinical outcome data. The deck cites external literature on visceral versus subcutaneous fat and positions EVL as a disruptive obesity treatment, but company materials acknowledge that EVL products have not yet been submitted for regulatory clearance and remain in development. Without contemporaneous clinical trial data or regulatory interactions presented, the scientific and clinical claims rest largely on mechanistic rationale rather than trial outcomes, which investors would need to scrutinize further.

How an investor would read this deck

What draws attention

• Qualification and structure of the Tier 2 Regulation A offering, including SEC qualification date (September 1, 2016), termination date (August 31, 2017), security description, and any offering caps or minimums.
• Dependence of the EVL development program on proceeds from the Reg A raise, given that the company’s pipeline disclosure states that key EVL products had been prototyped but not submitted for regulatory clearance and that offering proceeds were required to complete development and bring them to mark
• Status and economics of the legacy Airbrush Liposculptor TCAL product line, which is framed as commercial‑stage in the deck but later reported as discontinued and undergoing retooling, including any revenue history and installed base.
• Regulatory pathway and risk profile for EVL as a novel minimally invasive visceral fat removal procedure aimed at treating obesity and metabolic syndrome, including anticipated classification, necessary trials, and time‑to‑approval.
• Capital needs beyond the initial $5 million Reg A raise, given the long timelines and costs associated with device development, regulatory clearance, clinical validation, and commercialization in obesity and metabolic disease markets.

Risks that stand out

• Regulatory risk that EVL devices and procedures, which had not been submitted for clearance at the time of the raise, may face protracted or unsuccessful regulatory review, delaying or preventing commercialization.
• Financing risk given that the Tier 2 Regulation A offering appears to have raised only a small fraction of its $5 million target as of mid‑2016, implying dependence on future capital raises in a challenging niche.
• Product and execution risk associated with discontinuing legacy Airbrush Liposculptor TCAL systems while retooling for new electromagnetically actuated devices, potentially leaving a revenue gap and requiring renewed market adoption.
• Clinical and market adoption risk that a novel visceral fat removal procedure such as EVL may not demonstrate sufficient safety, efficacy, or economic advantage over established bariatric surgery and pharmacologic obesity treatments to achieve widespread physician and payer acceptance.
• Concentration risk because the company’s strategy hinges on a narrow set of interrelated technologies (TCAL and EVL) targeting obesity and metabolic disease, leaving limited diversification if the core thesis fails.

Questions this deck invites

• What were the final aggregate proceeds and number of investors in the 2016–2017 Tier 2 Regulation A offering, beyond the $5,200 raised as of June 3, 2016 reported in the Form 1‑K, and how were those funds allocated across EVL development, r
• What specific preclinical and clinical studies (design, endpoints, sample sizes) have been completed or are planned to support regulatory clearance and commercialization of the EVL procedure and devices, and what interim data (if any) exist
• How did the discontinuation and retooling of the Airbrush Liposculptor TCAL product line impact revenue, cash flow, and physician relationships, and what are the commercial launch plans, timelines, and pricing strategy for the new electroma
• What is the intended reimbursement and health‑economic strategy for EVL relative to bariatric surgery and other obesity treatments, including anticipated procedure codes, payer engagement, and cost‑effectiveness assumptions?
• How does the company plan to manage regulatory, clinical, and commercial risks if additional capital beyond the Reg A offering is required, and what contingency plans exist if regulatory clearance for EVL is delayed or denied?

What founders can take from the BioSculpture Technology, Inc. deck

• A Tier 2 Regulation A offering can be used by a small medical device company to fund development and clinical testing of novel devices and procedures, but attracting sufficient investor demand is challenging and may result in proceeds far below the initial target.
• Positioning a technology as a disruptive alternative in obesity and metabolic disease requires not only mechanistic rationale but also clear regulatory pathways and concrete evidence plans, which sophisticated investors will scrutinize closely.
• Highlighting the transition from a legacy commercial product line (such as Airbrush Liposculptor TCAL systems) to a next‑generation platform can be compelling, but investors will expect transparent disclosure of past commercial performance and the risks of discontinuing existing products.
• Investor presentations that lean heavily on forward‑looking statements and projections without corresponding clinical data, regulatory milestones, or detailed commercialization plans may face skepticism, particularly in highly regulated therapeutic areas.
• When a capital raise is essential to complete development and regulatory work, decks should explicitly address contingency plans, alternative financing options, and staged milestones to reassure investors about risk management.
• Niche device companies pursuing complex indications like obesity, metabolic syndrome, and type 2 diabetes need to clearly articulate reimbursement, competition, and adoption strategies to bridge the gap between technical innovation and commercial viability.

BioSculpture Technology, Inc. pitch deck: common questions

What does BioSculpture Technology, Inc. do?

BioSculpture Technology, Inc. is a medical device company developing patented Twin Cannula Assisted Liposuction (TCAL) systems and a minimally invasive endoscopic visceral lipectomy (EVL) procedure intended to remove visceral or “belly” fat as a treatment for obesity, metabolic syndrome, and type 2 diabetes mellitus.

What capital raise was this 2016 pitch deck supporting?

The company pursued a Tier 2 Regulation A offering qualified by the SEC on September 1, 2016, seeking to raise up to $5 million to fund development, clinical testing, and commercialization of its EVL procedure and related devices. The offering was described as part of its plan to become a public company.

Did BioSculpture’s 2016 Regulation A+ offering successfully raise the $5 million target?

According to the company’s investor and regulatory filings, the Tier 2 Regulation A offering was qualified on September 1, 2016 and terminated on August 31, 2017. A 2017 Form 1‑K filing reported that as of June 3, 2016, only 1,500 shares had been sold, raising approximately $5,200, indicating limited investor uptake.

What is the current status of BioSculpture’s products mentioned in the deck?

BioSculpture’s current materials state that its legacy Airbrush Liposculptor systems are no longer available or serviced as production is being retooled for a new generation of electromagnetically actuated Twin Cannula Assisted liposuction handpieces, while its EVL procedure remains under development and has not yet been submitted for regulatory clearance. This indicates that, post‑offering, the company remained in the development and pre‑clearance phase rather than broad commercial rollout.

What was the main clinical and commercial thesis of the deck?

The deck and company materials emphasize removal of both subcutaneous fat (via Airbrush Liposculptor TCAL devices) and visceral fat (via the EVL procedure), citing literature on the distinct health impacts of visceral adiposity. The claimed advantage is a minimally invasive approach to visceral fat that could offer an alternative to bariatric surgery for certain obese patients, though the company notes that its EVL products had not yet been submitted for regulatory clearance at the time and remain developmental.

Sources

Funding and outcome facts on this page were researched on 2026-08-22 from the pages below.

• Investors
• Notice of Qualification - SEC.gov
• EVL NEWS
• Patents
• BioSculpture Technology, Inc. Form 1-K Filed 2017-06-12
• [PDF] BioSculpture Technology, Inc.
• Mail Prccssing
• BioSculpture Technology, Inc. IPO

BioSculpture Technology, Inc. pitch deck slides

What each slide of the BioSculpture Technology, Inc. pitch deck says

Slide 1

4 Investor Presentation - Highlights Cc September 10, 2016 u L P [ECHNDOLOGY ANC. 7] i BST

Slide 2

. . 1 Disclaimer REGULATION A+ Allows companies to raise up to $50M from retail investors in an SEC registered offering. REGULATION D - RULE 506(c) Allows companies to raise capital from accredited investors only and market the offering. BIOCULPTURE TECHNOLOGY, INC. (“BIOCULPTURE”) HAS LAUNCHED A TEST THE WATERS CAMPAIGN FOR A REGULATION A+ OFFERING. WE ARE NOW ACCEPTING NON-BINDING INDICATIONS OF INTEREST (RESERVATIONS) NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED FOR OUR REGULATION A+ OFFERING AT THIS TIME AND IF SENT IN TO BIOCULPTURE WILL NOT BE ACCEPTED. NO OFFER TO BUY SECURITIES IN A REGULATION A+ OFFERING OF BIOCULPTURE CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE…

Slide 3

Forward Looking Statements 2 Any forecasts and pro forma financial information contained herein or which are part of the Company's business plan, are for illustrative purposes only and are based upon assumptions made by Management regarding hypothetical future events. Management believes these assumptions are reasonable and furthermore to the best of its knowledge that all the facts contained herein are true and there are no material errors or omissions. There 1s no assurance that actual events will correspond with the assumptions or that factors beyond the control of the Company will not affect the assumptions and adversely affect the illustrative value and conclusions of any forecasts. A…

Slide 4

BioSculpture Technology, Inc. Company Profile = Company Profile Key Financials = BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer FQE 6/30/16 $1,000's developing a patented minimally invasive method ji . 2016 2017 2018 2019 2020 and device for the endoscopic removal of visceral ~~ gaygg $0 $1909 $20,050 S$3L104 $44536 or “belly” fat as a new treatment of obesity, EBITDA ($2,401) ($398) $2,844 $4,987 $7,480 metabolic syndrome and type 2 diabetes mellitus. NFTINCOME ($2572) ($533) $2687 $4433 $4761 = Large IP portfolio: 3 patents on method and device with numerous more U.S. pending. = Proven concept: first generation of successful technology was licensed…

Slide 5

Experienced Management Team 5 Name Title Background Robert L. Founder, = Inventor of both PAL and TCAL; board-certified plastic and reconstructive Cucin, MD, President and general surgeon. FACS & CEO = BA (Cornell), M.D. (Cornell), JD (Fordham), MBA (Columbia). = 18 patents, 5 books, 24 articles, and one ballet score. = Founded and Directs Rocin Laboratories, Inc., a biomedical Research and Development company which licensed his first liposuction patent non- exclusively to NuMed, UAM, Byron Medical, Mentor, and Ethicon. = Founded and directed Plastic Surgical Research to support IACUC studies and clinical IRB's carried out at academic centers. = Founded and Directed the American Institute o…

Slide 6

Advisory Board G Name Title Background Peter Engineering * BS and MS in Materials Science and Engineering from the University of Ciriscioli, Consultant California and a PhD in Mechanical Engineering from Stanford University. BS MS PhD = Director of JLTV Programs for BAE Systems, Program Manager of the Engineering Mechanics Laboratory at General Electric Corporate Research. = Director of Research for the Fiberite Corporation where he led 30 engineers and scientists in U.S., U.K. and Europe and was responsible for the strategy and implementation of new technologies and products. = 4 patents, two books, and more than 20 published journal articles. Brigadier Medical = Yale B.S. and M.D, Board-c…

Slide 8

Different Fat Requires Different Treatments 8 Endoscopic Visceral Lipectomy with EVL® Liposuction with Airbrush® Liposculptor ITE = Visceral fat removal ' = Subcutaneous fat removal / Figure: CT sections at L3 level of the two subjects 51-year-old man (left) and 53-year-old woman (right). The left image also shows calcifications of the abdominal aorta and nephrosclerosis. Bazzocchi, A Diano, D Battista G How Fat is Fat? Lancet 380:1 (2012) » Accumulation of subcutaneous and visceral types of fat has different consequences for human body and EVL® and Airbrush® Liposculptor IIE provide viable and economic solutions for effective removal of both types of fat iBST rE0PO Yy

Slide text above is read directly from the BioSculpture Technology, Inc. deck PDF embedded on this page.

Related fundraising guides (24)

• EnergyX Pitch Deck Teardown: A Masterclass in Industrial Validation and Scientific Pedigree
• Chattermill Pitch Deck Teardown: A Masterclass in Enterprise Social Proof and Expansion Strategy
• Anja Health Pitch Deck Teardown: A Narrative-Led Approach to Cord Blood Banking
• Swipes Pitch Deck Teardown: A Minimalist Approach to Productivity Fundraising
• Hourly Pitch Deck Teardown: Connecting Payroll Data to Real-Time Workers' Comp Premiums
• Evy Pitch Deck Teardown: A 10-Slide Masterclass in Embedded Insurance Minimalism
• Clutch Wallet Pitch Deck Teardown: A $800k Pre-Seed Bet on Web3 Inclusivity
• Assembly Pitch Deck Teardown: A Product-First Series A Narrative Focused on Retention
• Cove.Tool Pitch Deck Teardown: A Masterclass in Visualizing Efficiency Gains
• IRLY Pitch Deck Teardown: A Gen-Z Dating Playbook Built on Video-First Interaction
• FX HedgePool Pitch Deck Teardown: Disintermediating the $66 Trillion FX Swap Market
• Cowboy Pitch Deck Teardown: A Masterclass in High-End Lifestyle Branding and Urban Mobility
• Beam Dental Pitch Deck Teardown: A Masterclass in Structural Cost Advantage
• 10KC Pitch Deck Teardown: A $56M Growth Round Built on Enterprise Social Proof
• micro1 Pitch Deck Teardown: Leveraging Growth Momentum and AI Vetting for Global Engineering
• Halp Pitch Deck Teardown: A 7-Slide Memo Strategy for a $4M Seed Round
• Dame Pitch Deck Teardown: A $7M Series A Masterclass in Normalizing Stigmatized Consumer Goods
• Bramble Energy Pitch Deck Teardown: Leveraging PCB Supply Chains for Hydrogen Fuel Cells
• AgBiome Pitch Deck Teardown: A $116M Series D Masterclass in Platform Validation
• Yuzu Health Pitch Deck Teardown: A Masterclass in Market Education and Infrastructure Replacement
• Hervé Pitch Deck Teardown: Scaling Luxury Cannabis Edibles Through Proprietary Hardware
• EcoVadis Pitch Deck Teardown: A Masterclass in Growth-Stage Market Dominance
• Calico Pitch Deck Teardown: A 6-Slide Masterclass in Supply Chain Simplification
• Alphin Pitch Deck Teardown: A $6M Series A Masterclass in Local SMB Digitization

Decks from the same year (1)

• 2016 pitch deck examples

Decks from the same region (1)

• US pitch deck examples

Browse companies alphabetically (1)

• Pitch decks from companies starting with B

More pitch deck teardowns (16)

• Biocon 11 Pitch Deck Teardown: Scaling a Global Biosimilars Powerhouse
• Biodel Inc. Pitch Deck Teardown: Leveraging Formulation IP for Diabetes Market Dominance
• Biogrify Pitch Deck Breakdown: A Visual Social Network for Infographic Storytelling
• Biomarker Pitch Deck Teardown: Quantifying the $3.7 Trillion Wellness Data Fragmentation
• Biomarker Labs Pitch Deck Breakdown: Quantifying the $3.7 Trillion Wellness Industry
• Biopane Energy Pitch Deck Teardown: A Blockchain Solution for African Power Distribution
• BioPolynet Pitch Deck Teardown: A Technical Solution for Industrial Tailings Management
• BioSculpture Pitch Deck Teardown: A Deep Dive into MedTech Fat Removal Innovation
• Bioshock Pitch Deck Breakdown: Selling a Narrative Vision for the First-Person Shooter
• BioTime Pitch Deck Teardown: A Public Market Roadmap for Regenerative Medicine
• BioVie Pitch Deck Teardown: Targeting Advanced Liver Cirrhosis with Clinical Data
• Birdie Pitch Deck Breakdown: A 9-Slide Masterclass in Market Urgency and Traction
• Bitcoin Company Pitch Deck Breakdown: A Crypto Template With No Crypto In It
• Bitdharma LLC Pitch Deck Teardown: A Crypto-Centric SMB Management Vision
• Bitdharma Pitch Deck Breakdown: $10M A Day, A 0.01% Fee, And Nobody's Name On It
• Bit Gold Pitch Deck Teardown: Scaling Gold-Backed Digital Payments

Recently published pitch deck teardowns (12)

• Dado Pitch Deck Breakdown: A Product-Focused Approach to HR Workflow Automation
• Curastory Pitch Deck Breakdown: Solving the Creator Monetization Gap with Video Royalties
• Curio Pitch Deck Breakdown: The $9M Series A Strategy for Premium Audio Journalism
• Curve Health Pitch Deck Breakdown: Leveraging Clinical Proof to Bridge Senior Care Silos
• Datagen Pitch Deck Breakdown: Solving the AI Data Bottleneck with Synthetic Humans
• Databricks Series D Pitch Deck Breakdown: Dominating the Unified Analytics Market
• Dayforward Pitch Deck Breakdown: The Full-Stack Strategy for D2C Life Insurance
• Deep Genomics Pitch Deck Breakdown: Scaling AI-Driven RNA Therapies for $180M Series C
• Dealflicks Pitch Deck Breakdown: A Masterclass in Traction-First Storytelling
• Devoted Health Pitch Deck Breakdown: A Masterclass in Unit Economics and Financial Modeling
• Devanthro Pitch Deck Breakdown: Solving Elder Care Through Humanoid Telepresence
• Ditto Pitch Deck Breakdown: Replacing the Dating App Swipe with Autonomous AI Agents

Fundraising library · Pitch deck examples · Investor directory · Founder database